In the last decade alone, many new life-prolonging therapeutic options for this disease have emerged.1,2 A relatively novel treatment concept for this disease is targeted radioligand therapy, whereby a radioisotope is paired with a monoclonal antibody against a cancer-specific antigen, such as prostate-specific membrane antigen (PSMA), providing an elegant method of targeted radiation to the cancer whilst minimizing effects on normal tissue. This evidence concerns the gene FOLH1 and cancer.